- Record: found
- Abstract: not found
- Article: not found
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon ,
Benjamin Besse ,
Todd M Bauer ,
Enriqueta Felip ,
Ross A Soo ,
D Ross Camidge ,
Rita Chiari ,
Alessandra Bearz ,
Chia-Chi Lin ,
Shirish M Gadgeel ,
Gregory J Riely ,
Eng Huat Tan ,
Takashi Seto ,
Leonard P James ,
Jill S Clancy ,
Antonello Abbattista ,
Jean-François Martini ,
Joseph Chen ,
Gerson Peltz ,
Holger Thurm ,
Sai-Hong Ignatius Ou ,
Alice T Shaw
December 2018
December 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d9380343e379">Lorlatinib is a potent, brain-penetrant, third-generation
inhibitor of ALK and ROS1
tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity
was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had
CNS metastases and progression after ALK-directed therapy. We aimed to analyse the
overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive,
advanced non-small-cell lung cancer.
</p>